Please login to the form below

Not currently logged in
Email:
Password:

NDA Group names general manager of new Switzerland operation

Stephanie Krumholz-Bahner has held numerous senior roles

Drug development, pharmacovigilance and HTA consultancy NDA Group has named Stephanie Krumholz-Bahner as general manager of its new Swiss operation.

The arm, named NDA Regulatory Service Switzerland, will support NDA's global client base with a specific focus on Swiss development requirements, in addition to aiding its clients in the area with global drug development needs.

Krumholz-Bahner has expansive experience in the pharma industry, holding senior roles in European, US and international regulatory affairs at Roche and Cytos across multiple therapeutic areas, including metabolic, oncology and inflammation.

Commenting on her appointment, she said: “I am delighted to be joining NDA Group and leading the new operation in Switzerland. NDA is committed to supporting global regulatory strategies and submissions for our clients with a natural addition of Swiss specific expertise.

“This will also enable clients in the region to more easily engage in our global capabilities through our involvement in the Zurich area.”

Prior to joining the pharma industry, Krumholz-Bahner was a pharmacological consultant for a venture capital company.

Johan Strömquist, CEO of NDA Group, added: “Stephanie's diverse and extensive experience as well as her growing network of contacts in Switzerland and beyond will be a tremendous asset for our client to tap in to.

“Stephanie will serve as another perfect conduit for our clients into the broader capabilities of the NDA Group.”

19th March 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics